1. How to submit my research paper? What’s the process for publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or .pdf format to the submission email: jomb@ejournal.net.
2.Can I submit an abstract?
The journal publishes full research papers. So only full paper submission... [Read More]

Reproducibility Study of Prediction of Brain Tumors Response to Bevacizumab Treatment

N. Behzadfar1 and H. Soltanian-zadeh1,2
1.Control and Intelligent Processing Center of Excellence School of ECE, Faculty of Eng University of Tehran, Tehran,14395-515
2.Radiology Image Analysis Laboratory, Henry Ford Health System, Detroit, MI 48202, USA.
Abstract—Glioblastoma Multiform (GBM) is the most common cause of cancer death in both men and women. Bevacizumab is a recent therapy for stopping the tumor growth. The purpose of this paper is to present our reproducibility study of predicting response of the brain tumors to Bevacizumab treatment. This method allows physicians to select most effective treatment plans. We take two image series of patients before and after the treatment. After constructing Eigen images, we extract their statistical histogram features and then use regression analysis to develop a predictive model. Predictive models of response are developed with large regression coefficients (maximum R2=0.8). This method is dependent on the operator. To decrease the operator’s role, this method is repeated four times for each patient. Then, the average of the achieved results is used for regression analysis. As a result, the regression coefficient increases (maximum R2=0.86). The result of this approach is compared to that of a previous work at the University of Tehran showing excellent reproducibility of the proposed method.
 
Index Terms—histogram analysis, glioblastoma multiform, bevacizumab, prediction, eigen image, statistical features, repeatability

Cite: N. Behzadfar and H. Soltanian-zadeh, "Reproducibility Study of Prediction of Brain Tumors Response to Bevacizumab Treatment", Journal of Medical and Bioengineering, Vol. 3, No. 1, pp. 1-4, March 2014. Doi: 10.12720/jomb.3.1.1-4
Array
Copyright © 2013-2016 Journal of Medical and Bioengineering. All Rights Reserved
E-mail: jomb@ejournal.net